Absci GmbH is a generative AI drug creation company. It develops biologic drug candidates through an integrated platform that combines data generation, AI model training, de novo design and wet-lab validation.
AI-generated
Offering
Products & services
Industry:Pharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
AI-enabled drug creation with wet-lab data, de novo design of biologics, multiparametric lead optimization, and experimental validation in iterative cycles.
AI Target Discovery
AI-enabled identification of novel therapeutic targets using Reverse Immunology from patient samples, preparing antibody-target pairs for optimization and studies.
Biologics Partnerships
Partnerships with pharma, technology, and academic partners to develop differentiated biologics against challenging targets and share the AI drug creation platform.
Biologics Pipeline
Internal and partnered biologics programs, including ABS-201 and ABS-202, focused on cytokine biology and clinical development.
Comparisons
Absci GmbH in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank Absci GmbH by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once Absci GmbH has claimed this profile, we'll publish editorial articles and case studies here together.